Context Therapeutics Advances CTIM-76 in Clinical Pipeline

The latest announcement is out from Context Therapeutics ( (CNTX) ).

On January 14, 2025, Context Therapeutics announced that the first patient has been dosed in their Phase 1 clinical trial of CTIM-76, a CLDN6 x CD3 T cell engaging bispecific antibody. This trial marks a significant milestone in their clinical pipeline, targeting CLDN6-positive gynecologic and testicular cancers. The study aims to enroll up to 70 patients to assess safety, tolerability, and efficacy, with initial data expected in the first half of 2026. This development underscores Context’s potential impact on the treatment of CLDN6-positive cancers and further strengthens its position in the biopharmaceutical industry.

More about Context Therapeutics

Context Therapeutics Inc. is a biopharmaceutical company based in Philadelphia, focused on advancing T cell engaging bispecific antibodies for solid tumors. The company’s innovative portfolio includes products like CTIM-76, a Claudin 6 x CD3 bispecific antibody, among others aimed at treating various cancers.

YTD Price Performance: -13.45%

Average Trading Volume: 537,632

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $81M

For an in-depth examination of CNTX stock, go to TipRanks’ Stock Analysis page.